ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.921,95
-1,16%
S&P 500
5.077,62
-0,75%
Dow Jones
38.064,29
-0,84%
Euro vs US Dollar
1,06891
-0,25%
Bitcoin
60.655,28
-4,99%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Halozyme Therapeutics Incorporated (HALO)

  7. Halozyme Therapeutics Incorporated (HALO) News

HALO Halozyme Therapeutics Incorporated

38,45
-0,32 (-0,83%)
Zuletzt aktualisiert: 17:32:46
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Halozyme Therapeutics Incorporated HALO NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
-0,32 -0,83% 38,45 17:32:46
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
38,54 38,45 39,03 38,77
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
25.4.202422:45PRNUSMahesh Krishnan Elected to Halozyme's Board of Directors
23.4.202414:30PRNUSHalozyme to Report First Quarter 2024 Financial and..
04.3.202422:13EDGAR2Form PRE 14A - Other preliminary proxy statements
29.2.202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202422:07EDGAR2Form 144 - Report of proposed sale of securities
27.2.202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202423:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.2.202422:08EDGAR2Form 144 - Report of proposed sale of securities
27.2.202414:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
21.2.202400:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202400:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202400:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202400:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.2.202422:07EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20.2.202422:03EDGAR2Form 8-K - Current report
20.2.202422:01PRNUSHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL..
16.2.202423:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.2.202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.2.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.2.202412:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.2.202422:30PRNUSHalozyme To Report Fourth Quarter and Full Year 2023..
29.1.202422:15PRNUSHalozyme Announces Takeda Received European Commission..
23.1.202417:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18.1.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.1.202414:30PRNUSHalozyme Announces argenx Received Approval in Japan for..
17.1.202422:56EDGAR2Form 144 - Report of proposed sale of securities
17.1.202414:10EDGAR2Form 8-K - Current report
16.1.202422:26EDGAR2Form 144 - Report of proposed sale of securities
16.1.202414:15PRNUSHalozyme Announces Takeda Receives FDA Approval for HYQVIA®..
16.1.202407:15PRNUSHalozyme Announces Roche Receives European Commission..
12.1.202415:25PRNUSHalozyme to Host Investor Business Forum and Long-Term..
05.1.202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.12.202301:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.12.202322:40EDGAR2Form 144 - Report of proposed sale of securities
12.12.202322:21EDGAR2Form 144 - Report of proposed sale of securities
27.11.202314:00PRNUSHalozyme to Present at Upcoming Investor Conferences
16.11.202322:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.11.202315:00PRNUSHalozyme Announces argenx Receives European Commission..
15.11.202322:17EDGAR2Form 144 - Report of proposed sale of securities
14.11.202322:19EDGAR2Form 144 - Report of proposed sale of securities
06.11.202322:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06.11.202322:04EDGAR2Form 8-K - Current report
06.11.202322:01PRNUSHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING..
06.11.202313:30PRNUSHalozyme and Acumen Pharmaceuticals Enter Global..
30.10.202323:35PRNUSHalozyme To Report Third Quarter 2023 Financial and..
19.10.202313:15PRNUSPositive Topline Results Reported from Bristol Myers..

Kürzlich von Ihnen besucht

NASDAQ
HALO
Halozyme Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten